| Literature DB >> 28785002 |
Shih-An Liu1,2,3, Chen-Chi Wang4,5, Rong-San Jiang4, Fang-Yi Lee6, Wen-Jiun Lin4, Jin-Ching Lin7,5.
Abstract
We investigated the relationship of different primary subsites together with their pathological features on the survival of oral cavity squamous cell carcinoma (OCSCC) patients. We retrospectively reviewed OCSCC patients and documented their demographic data, pathological features and clinical outcome. The Cox proportional hazard model was used to examine the influence of various pathological features on the prognosis in different subsites of oral cavity. There were totally 1,383 OCSCC patients enrolled for final analysis. Perineural invasion had a poor prognosis at the early stage of OCSCC patients especially those with primary at the tongue. In addition, lymphovascular invasion was associated with poor survival at the late stage especially those with primary at the buccal mucosa and the tongue. The impact of pathological features on the survival of OCSCC patients varied in different subsites. Further investigation is warranted to validate our finding in a multicenter study. Grouping the different markers to establish a prognostic scoring system may provide more accurate evaluation of the prognosis in OCSCC patients.Entities:
Mesh:
Year: 2017 PMID: 28785002 PMCID: PMC5547072 DOI: 10.1038/s41598-017-08022-w
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Comparison of variables among subsites of oral squamous cell carcinoma patients.
| Lip (n = 54) | Gum (n = 218) | FOM (n = 33) | Tongue (n = 417) | Buccal (n = 556) | Palate (n = 74) | RMT (n = 27) |
| |
|---|---|---|---|---|---|---|---|---|
| Age [Mean (SD)] | 52.4(9.8) | 55.9(11.6) | 51.7(7.0) | 51.3(11.3) | 52.7(10.9) | 55.2(11.8) | 52.3(9.4) | <0.001 |
| Gender [Male (%)] | 53(98.1) | 203(93.1) | 37(100) | 364(87.3) | 541(97.3) | 72(97.3) | 27(100) | <0.001 |
| Smoking (%) | 48(88.9) | 182(83.5) | 35(94.6) | 319(76.9) | 504(90.6) | 60(81.1) | 26(96.3) | <0.001 |
| Betel quid (%) | 48(88.9) | 177(81.2) | 35(94.6) | 289(69.3) | 503(90.5) | 58(78.4) | 23(85.2) | <0.001 |
| Alcohol (%) | 39(72.2) | 165(76.7) | 36(97.3) | 278(66.7) | 413(74.3) | 50(67.6) | 20(74.1) | 0.002 |
| Histological grade | 0.004 | |||||||
| WD (%) | 10(18.5) | 16(7.3) | 2(5.4) | 22(5.3) | 62(11.2) | 9(12.2) | 1(3.7) | |
| MD (%) | 35(64.8) | 161(73.9) | 26(70.3) | 280(67.1) | 360(64.7) | 47(63.5) | 23(85.2) | |
| PD (%) | 9(16.7) | 41(18.8) | 9(24.3) | 115(27.6) | 134(24.1) | 18(24.3) | 3(11.1) | |
| Perineural invasion (%) | 11(20.4) | 33(15.1) | 9(24.3) | 131(31.4) | 119(21.4) | 5(6.8) | 6(22.2) | <0.001 |
| Lymphvascular invasion (%) | 7(13.0) | 50(22.9) | 12(32.4) | 138(33.1) | 132(23.1) | 12(16.2) | 9(33.3) | 0.001 |
| Extracapsular spread | 8(14.8) | 36(16.5) | 11(29.7) | 82(19.7) | 79(14.2) | 10(13.5) | 4(14.8) | 0.108 |
| Surgical margin <5mm (%) | 8(14.8) | 43(19.7) | 9(24.3) | 45(10.8) | 108(19.4) | 18(24.3) | 4(14.8) | 0.004 |
| Pathological stage | <0.001 | |||||||
| Stage I and II (%) | 35(64.8) | 55(25.2) | 14(37.8) | 188(45.1) | 235(32.3) | 42(56.8) | 13(48.1) | |
| Stage III and IV (%) | 19(35.2) | 163(74.8) | 23(62.2) | 229(54.9) | 321(57.7) | 32(43.2) | 14(51.9) | |
| Postoperative radiation (%) | 19(35.2) | 95(43.6) | 22(59.5) | 210(50.4) | 261(46.9) | 33(44.6) | 14(51.9) | 0.196 |
| Loco-regional recurrence (%) | 16(29.6) | 81(37.2) | 16(43.2) | 151(36.2) | 187(33.6) | 26(35.1) | 12(44.4) | 0.687 |
| Distant metastasis (%) | 3(5.6) | 14(6.4) | 5(13.5) | 45(10.8) | 59(10.6) | 3(4.1) | 4(14.8) | 0.174 |
| Cancer death (%) | 11(20.4) | 41(18.8) | 10(27.0) | 109(26.1) | 151(27.2) | 20(27.0) | 7(25.9) | 0.329 |
| 5-year DSS (all stage, %) | 85.76 | 81.39 | 68.89 | 74.56 | 77.58 | 75.18 | 85.25 | 0.4530 |
| Stage I and II (%) | 88.91 | 87.19 | 90.91 | 86.23 | 86.41 | 77.78 | 100 | 0.8745 |
| Stage III and IV (%) | 54.14 | 72.66 | 43.10 | 53.70 | 55.78 | 64.28 | 51.43 | 0.0256 |
SD: standard deviation; WD: well differentiated; MD: moderately differentiated; PD: poorly differentiated; FOM: floor of mouth; RMT: retromolar trigone; DSS: disease-specific survival.
Univariate analysis of the impact of clinic-pathological features on the survival of oral squamous cell carcinoma patients based on subsites.
| Lip | Gum | Floor of mouth | Tongue | Buccal | Palate | RMT | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | HR | 95% CI | HR | 95% CI | HR | 95% CI | HR | 95% CI | HR | 95% CI | HR | 95% CI | |
| Age >50 years | 0.64 | 0.11–1.31 | 0.60 | 0.33–1.12 | 0.35 | 0.07–1.64 | 0.87 | 0.60–1.27 | 0.99 | 0.72–1.36 | 0.71 | 0.29–1.75 | 1.17 | 0.21–6.42 |
|
| ||||||||||||||
| MD vs. WD | 3.16 | 0.40–25.00 | 1.06 | 0.32–3.50 | 33.18 | 0–>10000 | 2.69 | 0.66–11.04 |
| 1.64–12.16 | 1.50 | 0.33–6.78 | 27.25 | 0–>10000 |
| PD vs. WD | 1.39 | 0.09–22.34 | 1.70 | 0.46–6.33 | 1.01 | 0–>10000 |
| 1.79–30.23 |
| 2.71–20.87 | 2.73 | 0.56–13.20 | 1.00 | 0–>10000 |
| PNI | 1.46 | 0.39–5.53 |
| 1.42–5.67 | 1.66 | 0.33–8.31 |
| 1.97–4.20 |
| 1.70–3.36 | 3.34 | 0.97–11.47 | 2.12 | 0.39–11.61 |
| LVI |
| 1.47–17.31 |
| 2.53–9.18 | 1.08 | 0.28–4.20 |
| 2.81–6.08 |
| 2.33–4.49 |
| 1.33–9.82 | 800.0 | 0.12–>10000 |
| ECS |
| 1.16–13.65 |
| 1.06–5.09 | 0.38 | 0.05–3.00 |
| 2.82–6.15 |
| 2.12–4.33 | 0.54 | 0.12–2.32 |
| 1.07–56.40 |
| Margin <5 mm | 3.56 | 0.94–13.54 |
| 1.30–5.02 |
| 3.01–84.79 |
| 1.39–3.68 |
| 1.28–2.69 | 0.95 | 0.35–2.62 | 0.04 | 0–7003 |
| Late stage |
| 1.59–22.80 |
| 1.01–5.73 |
| 0.94–58.33 |
| 2.95–7.57 |
| 2.25–4.85 |
| 1.11–7.02 | 85.89 | 0.11–67070 |
Abbreviations: RMT, retromolar trigone; HR, hazard ratio; CI, confidence interval; WD, well differentiated; MD, moderately differentiated; PD, poorly differentiated; PNI, perineural invasion; LVI, lymphovascular invasion; ECS, extra-capsular spread.
Multivariate analysis of the impact of clinic-pathological features on the survival of oral squamous cell carcinoma patients based on subsites.
| Lip | Gum | Floor of mouth | Tongue | Buccal | Palate | RMT | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | HR | 95% CI | HR | 95% CI | HR | 95% CI | HR | 95% CI | HR | 95% CI | HR | 95% CI | |
| Age >50 years | 0.96 | 0.11–8.25 | 0.52 | 0.25–1.09 | 0 | 0–>10000 | 0.97 | 0.66–1.42 | 0.94 | 0.68–1.30 | 0.36 | 0.12–1.07 | 0.22 | 0–>10000 |
|
| ||||||||||||||
| MD vs. WD | 0.90 | 0.09–9.55 | 0.81 | 0.24–2.80 | >1000 | 0–>10000 | 1.31 | 0.31–5.50 | 2.64 | 0.96–7.28 | 1.84 | 0.37–9.20 | 0.68 | 0–>10000 |
| PD vs. WD | 0.26 | 0.01–6.30 | 0.93 | 0.22–3.95 | >1000 | 0–>10000 | 2.17 | 0.50–9.46 |
| 1.31–10.49 | 3.03 | 0.57–16.21 | 0.57 | 0–>10000 |
| PNI | 0.25 | 0.04–1.47 | 1.14 | 0.47–2.77 | 10.50 | 0.57–194.4 |
| 1.03–2.31 | 1.14 | 0.77–1.68 | 4.33 | 0.91–20.56 | 0.18 | 0.09–96.36 |
| LVI | 6.78 | 0.71–64.29 |
| 1.31–6.91 | >1000 | 0–>10000 |
| 1.08–2.81 |
| 1.28–2.70 | 3.26 | 0.78–13.69 | >1000 | 0–>10000 |
| ECS | 0.91 | 0.09–8.94 | 1.12 | 0.40–3.13 | 0 | 0–>10000 | 1.51 | 0.95–2.39 | 1.43 | 0.95–2.16 | 0.11 | 0.02–0.59 | 1.74 | 0.19–15.79 |
| Margin <5 mm | 4.45 | 0.44–44.88 |
| 1.31–6.63 | 3.34 | 0.53–21.08 | 1.45 | 0.88–2.40 |
| 1.12–2.46 | 1.10 | 0.34–3.53 | 0 | 0–>10000 |
| Late stage | 5.53 | 0.74–41.46 | 1.88 | 0.73–4.84 | 71.38 | 0.67–7580 |
| 1.35–4.05 |
| 1.36–3.18 |
| 1.75–17.74 | 1.99 | 0–>10000 |
Abbreviations: RMT, retromolar trigone; HR, hazard ratio; CI, confidence interval; WD, well differentiated; MD, moderately differentiated; PD, poorly differentiated; PNI, perineural invasion; LVI, lymphovascular invasion; ECS, extra-capsular spread.
Figure 1Univariate analysis of the presence of perineural invasion (PNI) on disease-specific survival stratified according to initial pathological stage in tongue squamous cell carcinoma patients.
Figure 2Univariate analysis of the presence of lymphovascular invasion (LVI) on disease-specific survival stratified according to initial pathological stage in tongue and buccal squamous cell carcinoma patients.
Multivariate analysis of the impact of clinic-pathological features on the survival of oral squamous cell carcinoma patients based on pathological stage and subsites (the tongue and the buccal mucosa only).
| All (n = 1383) | All Stage I & II (n = 582) | All Stage III & IV (n = 801) | Tongue Stage I & II (n = 188) | Tongue Stage III and IV (n = 229) | Buccal Stage I & II (n = 235) | Buccal Stage III & IV (n = 321) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | HR | 95% CI | HR | 95% CI | HR | 95% CI | HR | 95% CI | HR | 95% CI | HR | 95% CI | |
| Age >50 years | 0.83 | 0.67–1.03 | 0.81 | 0.51–1.29 | 0.81 | 0.64–1.04 | 0.69 | 0.29–1.63 | 0.96 | 0.62–1.47 | 0.68 | 0.34–1.34 | 0.98 | 0.68–1.43 |
|
| ||||||||||||||
| MD vs. WD | 1.72 | 0.96–3.11 | 1.63 | 0.70–3.84 | 1.66 | 0.73–3.77 | 0.78 | 0.16–3.82 | >1000 | 0–>10000 | 3.08 | 0.72–13.13 | 2.17 | 0.52–9.00 |
| PD vs. WD |
| 1.25–4.25 | 2.17 | 0.83–5.67 | 2.16 | 0.93–5.01 | 1.85 | 0.34–9.97 | >1000 | 0–>10000 | 4.75 | 0.98–22.92 | 3.01 | 0.71–12.70 |
| PNI |
| 1.07–1.72 |
| 1.31–4.21 | 1.24 | 0.96–1.60 |
| 1.38–10.54 | 1.29 | 0.83–2.00 | 0.76 | 0.22–2.59 | 1.10 | 0.72–1.67 |
| LVI |
| 1.59–2.63 | 0.84 | 0.30–2.36 |
| 1.63–2.80 | 0.23 | 0.03–1.90 |
| 1.16–3.26 | 0.49 | 0.07–3.64 |
| 1.32–2.91 |
| ECS | 1.16 | 0.89–1.51 | 1.16 | 0.89–1.52 | 1.47 | 0.93–2.34 | 1.46 | 0.97–2.22 | ||||||
| Margin <5 mm |
| 1.37–2.27 | 1.29 | 0.66–2.53 |
| 1.41–2.43 |
| 1.18–15.53 | 1.19 | 0.68–2.08 | 1.05 | 0.36–3.03 |
| 1.20–2.86 |
| Late stage |
| 1.71–3.03 | ||||||||||||
Abbreviations: RMT, retromolar trigone; HR, hazard ratio; CI, confidence interval; WD, well differentiated; MD, moderately differentiated; PD, poorly differentiated; PNI, perineural invasion; LVI, lymphovascular invasion; ECS, extra-capsular spread.
Results of application of the scoring system to 1383 patients.
| Score | No. of patients (% in column) | No. of loco-regional recurrence (%) |
|---|---|---|
| 7 | 82 (5.9) | 18 (22.0) |
| 8 | 349 (25.2) | 114 (32.7) |
| 9 | 308 (22.3) | 109 (35.4) |
| 10 | 168 (12.1) | 59 (35.1) |
| 11 | 127 (9.2) | 56 (44.1) |
| 12 | 134 (9.7) | 44 (32.8) |
| 13 | 98 (7.1) | 41 (41.8) |
| 14 | 88 (6.4) | 32 (36.4) |
| >15 | 29 (1.8) | 16 (55.2) |
Figure 3Receiver operator characteristic (ROC) curve for cutoff analysis of score in patients with loco-regional recurrence. The area under the curve is 0.547. The table represents statistical parameters calculated for different cutoff values to predict loco-regional recurrence.